Pleioflow-RF
Clinical- Indications
- Acute kidney injury, Renal failure in cardiac surgery
Company intelligence / Profile preview
Pleioflow
United Kingdompleioflow.com ↗
- Ownership
- Private
- Development stage
- Clinical
01
Overview
Pleioflow’s lead product—a percutaneous flow assist device—has shown promising early results in a first-in-human clinical trial. All treated patients so far have achieved technical and functional success with restoration of baseline renal function at discharge. The company aims to complete the pilot study and obtain CE Mark in Europe and FDA breakthrough designation in the US
- Therapeutic areas
- NeurologyCardiovascularNephrology
- Modalities
- Device
- Industry
- Therapeutic Medical Devices
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on Pleioflow.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pleioflow.